Nippon Venture Capital
VC Fund
Tokyo, Japan
Nippon Venture Capital is a VC fund in Tokyo focused on Software and Health Care. Nippon Venture Capital ("NVCC"), established in 1996 as one of the few largest Japanese independent venture capital firms, is destined to undertake the unprecedented task of providing full-range venture capital services in cooperation with major Japanese business leaders and leading companies, which have supported and nurtured various newbusinesses on their own, as well as proactively developing new venture enterprises.
- Total investments:
- 203
- Last investment:
- Lead investor:
- 17%
- Fund size:
- $15M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Nippon Venture Capital invests in
Stages Nippon Venture Capital invests in
Countries Nippon Venture Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $1.5M–$45M
- Series B
- $3.3M–$33M
- Venture - Series Unknown
- $457k–$12M
Investment Focus
Industry
- Software 21 (10%)
- Health Care 21 (10%)
- Medical 18 (9%)
- Information Technology 18 (9%)
- Biotechnology 17 (8%)
Stage
- Venture - Series Unknown 66 (33%)
- Series A 34 (17%)
- Series B 28 (14%)
- Seed 25 (12%)
- Funding Round 14 (7%)
Country
- Japan 154 (76%)
- United States 6 (3%)
- Indonesia 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Kakiuchi Shingo
General Manager
|
General Manager | Total investments: 1 | Find email | |
Anzai Hiroaki
Venture Capitalist
|
Venture Capitalist | Total investments: 2 | Find email | |
Chihiro Kanagawa
Director
|
Director | Total investments: 0 | Find email | |
|
Yuko Kitaoka
Senior Partner
|
Senior Partner | Total investments: 1 | Find email | |
Yuyang Liu
Capitalist
|
Capitalist | Total investments: 7 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| AOI Biosciences is a biotechnology company that creates testing and drug discovery businesses. | $3.2M / Venture - Series Unknown / Sep 14, 2026 | ||
| KUZEN provides enterprise-grade chatbot technologies, especially the bot framework and NLP, via a visual UI without coding. The company is utilizing technology to develop a system that broadens the scope of dialogue. They use technology to provide their customers with next-generation standard procedures that broaden the possibilities ofconversation, resulting in unprecedented business practices. | Secondary Market / Jul 07, 2026 | ||
| KUZEN provides enterprise-grade chatbot technologies, especially the bot framework and NLP, via a visual UI without coding. The company is utilizing technology to develop a system that broadens the scope of dialogue. They use technology to provide their customers with next-generation standard procedures that broaden the possibilities ofconversation, resulting in unprecedented business practices. | $10.1M / Series B / Jul 07, 2026 | ||
| Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses. | $32.8M / Series B / Jun 30, 2026 | ||
| Space BD aims to become a one-stop shop to respond to all issues related to industrialization of space, and alleviate the work of businesses that are developing new technologies. | $6.8M / Series C / Jun 17, 2026 | ||
| MENOU specializes in AI technology and sensing technology. It features a graphical image identification modeler software. | $3.3M / Series B / Jun 01, 2026 | ||
| Movus Technologies Indonesia is automotive company that provides car ownership rental services. | $10.5M / Series B / May 15, 2026 | ||
| Restore Vision is a biotechnology company developing a visual restoration gene therapy for retinitis pigmentosa. Restore Vision develops eye disease therapeutic agents. | $8.2M / Series B / Apr 15, 2026 | ||
| Metagen Therapeutics (MGTx) is a clinical-stage company operating Japan’s first GMP-compliant manufacturing platform for fecal microbiota transplantation (FMT) therapies. The company combines proprietary paired metagenomic datasets with AI/ML-driven donor-recipient matching to advance precision microbiome medicine across ulcerative colitis,immuno-oncology, and neurodegenerative disease. Headquartered in Tsuruoka, Japan, MGTx leverages a cross-border regulatory strategy spanning PMDA and FDA pathways, positioning it as a platform bridging Japanese clinical innovation with global market access. | $7.7M / Series B / Feb 25, 2026 | ||
| SALESCORE cooperates with SFA to improve the efficiency of data entry, data analysis, and daily sales progress management, contributing to sales productivity and profit improvement. | $7.4M / Series B / Dec 08, 2025 | ||
| See all 203 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Nippon Venture Capital invest in?
Nippon Venture Capital invests primarily in Software, Health Care and Medical startups, most often at Venture - Series Unknown and Series A stage. Most of the 203 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Nippon Venture Capital's check size?
Nippon Venture Capital typically joins rounds of $1.5M–$45M at Series A, $3.3M–$33M at Series B and $457k–$12M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Nippon Venture Capital participates in.
How do I contact Nippon Venture Capital?
Public channels for Nippon Venture Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Nippon Venture Capital?
The team at Nippon Venture Capital includes Kakiuchi Shingo (General Manager), Anzai Hiroaki (Venture Capitalist) and Chihiro Kanagawa (Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
